Relationship between small intestinal bacterial overgrowth and severity of with hepatitis B cirrhosis

Wei XinPeng; Gao Xiao; Ma YingJie

doi:10.3969/j.issn.1001-5256.2016.04.021

Issue 4

Apr. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(4): 716-719

PDF( 2763 KB)

Relationship between small intestinal bacterial overgrowth and severity of with hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.04.021

Department of Gastroenterology, Zhengzhou People′s Hospital, Xinxiang Medical University

Published Date: 2016-04-20

Abstract

Abstract

Objective To investigate the relationship between small intestinal bacterial overgrowth( SIBO) and the severity of hepatitis B cirrhosis. Methods Forty- seven patients with hepatitis B cirrhosis who visited Department of Gastroenterology,Zhengzhou People's Hospital,from June 2014 to June 2015 were selected as cirrhosis group; these patients consisted of 11 Child- Pugh class A cases,16 Child-Pugh class B cases,and 20 Child- Pugh class C cases. Fifteen healthy volunteers were selected as control group. The levels of procalcitonin,bilirubin,plasma albumin,and globulin were measured in all subjects. The lactulose hydrogen breath test( LHBT) was performed to measure small intestinal bacterial growth. Comparison of categorical data was made by chi- square test or Fisher's exact test. Comparison of normally distributed continuacs data between groups was performed by t test,The correlations of SIBO with procalcitonin,bilirubin,plasma albumin,and albumin / globulin ratio were investigated by Pearson correlation analysis. Results SIBO was found in 22( 46. 8%) of the 47 patients with liver cirrhosis,consisting of 2( 18. 1%) in the 11 Child- Pugh class A cases,7( 43. 7%) in the 16 Child- Pugh class B cases,and 13( 65. 0%) in the 20 Child- Pugh class C cases. The prevalence of SIBO showed a significant difference between the controls and all patients with hepatitis B cirrhosis,Child- Pugh class B cases,or Child- Pugh class C cases( P = 0. 005,0. 037,or 0. 001),but no significant difference between the controls and Child- Pugh class A cases( P = 0. 556); there was a significant difference in the prevalence of SIBO between Child- Pugh class A cases and Child- Pugh class B / C cases( χ~2= 4. 727,P = 0. 030). The levels of procalcitonin,bilirubin,plasma albumin,and globulin were significantly correlated with LHBT set- value( r = 0. 895,0. 907,- 0. 810,and 0. 755,respectively,all P < 0. 001). Conclusion The prevalence of SIBO increases with exacerbation of liver injury in patients with hepatitis B cirrhosis. The levels of procalcitonin,bilirubin,and globulin are positively correlated with SIBO,while plasma albumin level is negatively correlated with SIBO.
- liver cirrhosis,
- hepatitis B,
- enterobacteriaceae

FullText(HTML)

References(16)

References

[1]CHEN YF,WU ZJ.Pathogenesis and risk factors of cholesterol gallstones in patients with non-alcoholic fatty liver disease[J].J Clin Hepatol,2013,29(12):952-955.(in Chinese)陈永芳,吴战军.非酒精性脂肪性肝病患者并发胆固醇性胆结石的发病机制及危险因素[J].临床肝胆病杂志,2013,29(12):952-955.

[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[3]PANDE C,KUMAR A,SARIN SK.Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease[J].Aliment Pharmacol Ther,2009,29(12):1273-1281.

[4]LOMBARDO L,FOTI M,RUGGIA O,et al.Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy[J].Clin Gastroenterol Hepatol,2010,8(6):504-508.

[5]ZHOU HY,ZHOU GH,LENG MF,et al.A study on small intestinal bacterial overgrowth in patients with cirrhosis[J].Chin J Diffic and Compl Cas,2011,10(3):185-187.(in Chinese)周红宇,周国华,冷明芳,等.肝硬化小肠细菌过度生长情况分析[J].疑难病杂志,2011,10(3):185-187.

[6]MORENCOS FC,de LAS HERAS CG,MARTIN RL,et al.Small bowel bacterial overgrowth in patients with alcoholic cirrhosis[J].Dig Dis Sci,1995,40(6):1252-1256.

[7]YANG CY,CHANG CS,CHEN GH.Small-intestinal bacterial overgrowth in patients with liver cirrhosis,diagnosed with glucose H2or CH4 breath tests[J].Scand J Gastroenterol,1998,33(8):867-871.

[8]WILBERG S,PIERAMICO O,MALFERTHEINER P.The H2-lactulose breath test in the diagnosis of intestinal transittime[J].Leber Magen Darm,1990,20(3):129-137.

[9]CAO SG,WU H,XU CL,et al.Effects of small intestinal bacterial overgrowth on bowel gas production in patients with liver cirrhosis[J].Chin JHepatol,2010,18(11):864-865.(in Chinese)曹曙光,吴昊,徐昌隆,等.肝硬化患者小肠细菌过度生长在肠道气体产生中的作用[J].中华肝脏病杂志,2010,18(11):864-865.

[10]LI SL,LIU XJ,ZHOU HT.The relation between hepatic cirrhosis and small intestine bacterial overgrowth[J].China Modern Med,2014,21(35):58-60.(in Chinese)李山林,刘学进,周洪涛.肝硬化与小肠细菌过度生长的关系[J].中国当代医药,2014,21(35):58-60.

[11]CHEN CY,LU CL,CHANG FY,et al.Delayed gastrointestinal transit in patients with hepatocellular carcinoma[J].J Gastroenterol Hepatol,2002,17(12):1254-1269.

[12]MORGENTHALER NG,STRUCK J,CHANCERCLLE Y,et al.Production of procalcitonin(PCT)in non-thyroidal tissue after LPS injection[J].Horm Metab Res,2003,35(5):290-295.

[13]The Organize of the Expert Consensus on the Clinical Application of Procalcitonin in Emergency.The expert consensus on the clinical application of procalcitonin in emergency[J].Chin J Emerg Med,2012,21(9):944-951.

[14]CONNERT S,STREMMEL W,ELSING C.Procalcitonin is a valid marker of infection in decompensated cirrhosis[J].Z Gastroenterol,2003,41(2):165-170.

[15]LESINSKA M,HARTLEB M,GUTKOWSKI K,et al.Procalcitonin and macrophage inflammatory protein-1 beta(MIP-1β)in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis[J].Adv Med Sci,2014,59(1):52-56.

[16]BOTA DP,van NUFFELEN M,ZAKARIAH AN,et al.Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver[J].J Lab Clin Med,2005,146(6):347-351.

Relative Articles

[1]	Wei YAN, Huifang HUANG. Effect of glucocorticoid in the treatment of severe drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(10): 2302-2307. doi: 10.3969/j.issn.1001-5256.2022.10.019
[3]	Yu HE, Jidong JIA, Ping WANG. Research advances in the role of the glucocorticoid-induced tumor necrosis factor receptor-related protein and its ligand in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(7): 1718-1723. doi: 10.3969/j.issn.1001-5256.2021.07.051
[4]	Long LIU, Yao LIU, Fangyuan GAO, Xianbo WANG. Clinical features of chronic liver disease with autoimmune blood diseases and the clinical effect of glucocorticoid[J]. Journal of Clinical Hepatology, 2021, 37(8): 1878-1882. doi: 10.3969/j.issn.1001-5256.2021.08.025
[5]	Yang Jun, Hu ZhongJie, Zhu YueKe, Yu HongWei, Li Juan, Hou Wei, Ning QiQi. Clinical effect of glucocorticoids versus pentoxifylline in patients with severe alcoholic liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1546-1550. doi: 10.3969/j.issn.1001-5256.2019.07.025
[6]	Zhao YouYou, Zhang Duan, Yin Xin, Wen XiaoYu, Gao PuJun. Glucocorticoid treatment of intrahepatic cholestasis caused by infectious cholangitis: A case report[J]. Journal of Clinical Hepatology, 2019, 35(2): 386-387. doi: 10.3969/j.issn.1001-5256.2019.02.031
[7]	Ma Juan, Liu YuLan. Corticosteroid therapy for autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1599-1603. doi: 10.3969/j.issn.1001-5256.2018.08.002
[9]	Wang XiuFang, Feng GuoHe. Research advances in glucocorticoids for the treatment of liver failure[J]. Journal of Clinical Hepatology, 2018, 34(7): 1565-1568. doi: 10.3969/j.issn.1001-5256.2018.07.043
[10]	Meng QingHua. Timing of glucocorticoid therapy for liver failure[J]. Journal of Clinical Hepatology, 2017, 33(9): 1683-1686. doi: 10.3969/j.issn.1001-5256.2017.09.011
[11]	Liu LiBin, Wang Min, Tian YueLi, Cong Jing, Wang LiYing. Severe fatty liver induced by glucocorticoids: a report of one case[J]. Journal of Clinical Hepatology, 2016, 32(1): 161-162. doi: 10.3969/j.issn.1001-5256.2016.01.034
[12]	Qiu Bo, Zhu Ling, Wang TangMing, Yan ShiChun, Zhang JianMing, Xie ZhiAn, Liu XingYu. Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(7): 1300-1304. doi: 10.3969/j.issn.1001-5256.2016.07.017
[13]	Chang BinXia, Teng GuangJu, Sun Ying, Zhao Jun, Zhang Wei, Zou ZhengSheng, Li BaoSen. Drug-induced liver injury caused by treatment of complications after glucocorticoid therapy for panniculitis: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(5): 775-776. doi: 10.3969/j.issn.1001-5256.2015.05.035
[14]	Ge HongYan, Wang YingShu. Clinical efficacy of glucocorticoid therapy in treatment of drug-induced cholestatic liver disease[J]. Journal of Clinical Hepatology, 2015, 31(10): 1618-1620. doi: 10.3969/j.issn.1001-5256.2015.10.014
[15]	Zhou XinMin, Dong XuYang. Therapeutic strategies of liver failure for clinical cases[J]. Journal of Clinical Hepatology, 2012, 28(2): 93-98.
[16]	Wang Meng, Nie QingHe. Meta-analysis of the efficacy and complications of glucocorticoids in patients with severe hepatitis-related liver failure [J]. Journal of Clinical Hepatology, 2012, 28(10): 764-770.
[17]	Zhou XianShan, Wan MoBin, Xue JianYa, Zhang Bin. Effects of glucocorticoids combined with antiviral therapy in treatment of patients with chronic severe hepatitis B.[J]. Journal of Clinical Hepatology, 2008, 24(2): 101-103.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	朱惠刚，刘东升，贾楷桥. 腹腔镜下精准肝切除术与常规腹腔镜肝肿瘤切除术治疗原发性肝癌的效果及安全性. 中西医结合肝病杂志. 2022(07): 648-650 .
2.	邓明，邓芳，陈志坚，周福生. 连翘苷对胃癌细胞AGS增殖、迁移和侵袭的抑制作用. 中成药. 2022(09): 3009-3012 .
3.	赵金磊，季春勇，石伟，罗红杰，季予江，刘东亮. 长链非编码RNA MIAT在肝细胞癌组织中的表达及临床意义. 临床肿瘤学杂志. 2021(03): 217-221 .
4.	侯亚萍，张小晶，李婷. 原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系. 肝脏. 2021(07): 757-760 .
5.	陈绪林，姜宇，赵艳，李彩华，高逸之. 原发性肝癌组织中miR-557的表达及其与预后的关系. 国际消化病杂志. 2021(04): 313-316 .
6.	杜小梅，吕建宁，李雯. 长链非编码RNA EXOC7在非小细胞肺癌中的表达及临床意义分析. 临床肺科杂志. 2020(04): 592-595 .
7.	林洁，黄炳臣，王娟，黄云美，黄小英. 肝癌患者组织及血清微小RNA-24和微小RNA-629的表达水平及其临床意义. 广西医学. 2020(14): 1775-1778 .
8.	梅洪亮，黄致远，胡逸林，江艳，陈敏，卢绮萍，刘志苏. 长链非编码RNA KCNQ1重叠转录物1在肝细胞癌迁移及增殖和侵袭中的作用与机制研究. 中华消化外科杂志. 2020(10): 1083-1090 .
9.	杨书才，张莉，刘利平，邓唯杰，周杰，刘慧，张鲍虎，金涛. 缺氧诱导因子2α对肝细胞癌化疗耐药性的影响. 中国临床药理学与治疗学. 2019(06): 630-636 .
10.	钟蓝海，马丹丹，张智勇，张翌，蔡逊. 基于数据挖掘分析FAM134B在肝癌中的表达及其与预后的关系. 临床肝胆病杂志. 2019(11): 2508-2512 . 本站查看
11.	唐丽，唐华，孙强. FOXM1、FOXO3a在肝癌中的表达及其临床意义. 临床医学研究与实践. 2019(36): 24-26 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2504) PDF downloads(401)

Relationship between small intestinal bacterial overgrowth and severity of with hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.04.021